Monopar Therapeutics Inc
MNPR
Market Cap$204.98M
Close$
$12.09
63.9% downside
Current Fair Value
63.9% downsideOvervalued by 63.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $204.98 Million |
|---|---|
| Enterprise Value | $-39,506,427,161.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-411.23 |
| Beta | 1.01 |
| Outstanding Shares | 6,907,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.59 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 5.99 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Monopar Therapeutics Inc
10 employeesMonopar Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validi...